Catalyst Dossier · compiled by CeliA 🧫
HealthLynked Corp (HLYK)
Services-Offices & Clinics of Doctors of Medicine · market cap $6M
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-15 (est.)
Phase 2
Pipeline
15
programs
Upcoming events
1
next 90d+
Dossier
Not yet
generate it
The catalyst path
- 2026-12-15 (est.)Phase 2 · EC5026 oral tabletimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Bevasiranib | Phase 2 | Macular Degeneration |
| Abaloparatide Transdermal (50 mcg) | Phase 2 | Post Menopausal Osteoporosis |
| Estradiol transdermal one 90 μL spray | Phase 3 | Hot Flashes |
| VeraCept | Phase 2 | Contraception |
| Danazol Once Weekly | Phase 2 | Endometriosis |
| IDP-122 Lotion | Phase 3 | Plaque Psoriasis |
| MOA-728 | Phase 3 | Constipation |
| plecanatide | Phase 3 | Chronic Idiopathic Constipation |
| ELND005 | Phase 2 | Alzheimer Disease |
| IDP-123 Lotion | Phase 3 | Acne Vulgaris |
| MCS-2 | Phase 3 | Lower Urinary Tract Symptoms |
| Balsalazide Disodium | Phase 3 | Inflammatory Bowel Disease |
| Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli) | Phase 3 | Human Papillomavirus Infection |
| Rifaximin | Phase 3 | Diarrhea |
| EC5026 oral tablet | Phase 2 | Parkinson's Disease (PD) |
Price & technical context
3-month
-9.7%
6-month
-7.2%
12-month
-44.3%
52-wk range
$1.26–$8.00
vs 50-day MA
+11.4%
vs 200-day MA
-29.9%
Realized vol
188.0%
Max drawdown
-86.0%
Daily closes through 2025-12-11. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for HLYK (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 15 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.